Skip to content

About
- About Us
- Management Team
Programs
- Amezosvatein for Shingles
- Amezosvatein for Chickenpox
Contact Us

News

Search for:

{"cpt":"blog","style":"3","columns":"3","show":"6","order":"DESC","orderby":"DESC"}

All
Events
News
Press Releases
Vaccines

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

16 Nov, 2022

Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines

by curevovaccine

Phase 2 Enrollment of CRV-101 Completed

15 Sep, 2022

Curevo Vaccine Announces Enrollment Complete in Phase 2b Trial of CRV-101 Vaccine Against Shingles

by curevovaccine

4 Comments

Curevo history 450x249

11 Feb, 2022

Vaccine startup Curevo takes on pharma giant GSK, raises $60M for trial of shingles shot

by curevovaccine

60 Million Funding Supports Shingles Vaccine Candidate 1200 x 800

11 Feb, 2022

$60 Million Funding Supports Shingles Vaccine Candidate

by curevovaccine

Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines 658x324

10 Feb, 2022

News, Press Releases, Vaccines

Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines

by curevovaccine

George-Simeon 2048 x 1152

10 Feb, 2022

A small Seattle biotech wants to take on GlaxoSmithKline’s emerging Shingrix blockbuster. RA Capital is on board

by curevovaccine

1 2 3 4

News

___________________

A wholly owned subsidiary of Eli Lilly and Company

Curevo Inc.
18911 N Creek Pkwy #150
Bothell, WA 98011

+1.206.492.5722

Terms of Use
Privacy Policy
Cookie Policy

Consumer Health Privacy Notice

© 2026 Curevo Inc.® All rights reserved.